Search Our Website
Evaluate Your Case Today
Calcagno & Associates
900 South Avenue, 3rd Floor
Staten Island, NY, 10314
Phone: 1-800-WE-FIGHT
(718) 568-3585
By appointment only
Battery Place
New York, NY, 10004
Phone: (800) 933-4448
Grand Concourse Bronx, NY, 10451 Phone: (718) 933-4448
Bay Parkway Brooklyn, NY, 11214 Phone: (800) 487-6837
Spiriva HandiHaler Linked to Increased Risk of Heart Attack and Stroke
The Spiriva HandiHaler, used to treat breathing problems in patients with chronic obstructive pulmonary disease (COPD), has been shown to dramatically increase the risk of heart attack and cardiovascular death. A Wake Forest University medical study released in September 2008 showed that tiotropium bromide, the active ingredient in the Spiriva HandiHaler, resulted in a 53 percent increased risk of heart attack, an 80 percent greater risk of cardiovascular death, and a 46 percent increased risk of stroke.
If you or a loved one used the Spiriva HandiHaler and suffered a heart attack, stroke, or cardiovascular death, you may have rights. You should speak with one of our qualified lawyers as quickly as possible to ensure that your legal rights are protected. We represents people across the United States who have been injured by dangerous drugs. We are available 24 hours a day, 7 days a week to discuss your case. Our law firm is available 24/7 to answer any questions you may have. Contact us today for a free, no obligation, legal consultation by completing the case evaluation form on the right side of this page or by calling 1-800-WE-FIGHT (1-800-933-4448).
What is the Spiriva HandiHaler?
The Spiriva HandiHaler is a maintenance bronchodilator that uses the active ingredient tiotropium bromide to reopen narrowed airways in the lungs to help improve breathing in patients with COPD. It was FDA-approved in 2004 and is not intended to treat sudden breathing spasms (bronchospasm). It has been used by millions of people worldwide.
Recent University Study Links Spiriva HandiHaler to Increased Health Risks
In September 2008, a study conducted by Wake Forest University Baptist Medical Center in Winston-Salem, N.C. found a link between the Spiriva HandiHaler and a greatly increased risk of heart attack, stroke, and cardiovascular death. The study focused on patients who took the inhaler for a month.
The researchers pooled data from 17 international studies involving 14,783 people and compared the health risks for people who used the Spiriva HandiHaler and a similar drug called Atrovent to treat COPD symptoms to risks for people who took other inhaled medications for the condition.
The study found people who took the Spiriva HandiHaler or Atrovent had an elevated risk of heart attack, stroke, and cardiovascular death when compared to people taking the generic drug albuterol, salmeterol (marketed by GlaxoSmithKline Plcas Serevent), or the combination of fluticasone and salmeterol (marketed by Glaxo as Advair), or a placebo.
Free Legal Consultation
If you or a loved one was prescribed the Spiriva HandiHaler for COPD or another cardiovascular condition and suffered a heart attack, stroke, or other cardiovascular disease, it is important to speak with a qualified personal injury lawyer as soon as possible. Recent medical research has linked the Spiriva HandiHaler to increased health risks. Our law firm is available 24/7 to answer any questions you may have. Contact us today for a free, no obligation, legal consultation by completing the case evaluation form on the right side of this page or by calling 1-800-WE-FIGHT (1-800-933-4448).
Return to Defective Drugs Listing